Study evaluates cryosupernatant for rodenticide coagulopathy in dogs
Bottom line
Retrospective data published in the Journal of Veterinary Emergency and Critical Care suggests cryosupernatant may be a workable transfusion option for dogs with suspected vitamin K antagonist rodenticide coagulopathy. In the seven-dog case series, drawn from a university teaching hospital’s records from 2000 to 2017, the median cryosupernatant dose was 11.0 mL/kg, prothrombin time improved significantly after transfusion, six dogs had resolution of clinical hemorrhage and were discharged, and no transfusion reactions were reported. All dogs also received vitamin K supplementation, while one dog was euthanized because of multi-organ dysfunction. The authors conclude that cryosupernatant could be considered as an alternative to fresh frozen plasma in this setting, despite its lower factor IX activity. (researchgate.net)
Why it matters: For veterinary professionals, the report adds a small but practical piece of evidence around blood product selection in emergency toxicology cases. Standard management of anticoagulant rodenticide toxicity centers on vitamin K₁ plus transfusion support when patients are actively bleeding or unstable, and Cornell’s diagnostic guidance specifically lists cryosupernatant among acceptable products for immediate factor replacement. That makes this paper less a practice-changing trial than an early signal that clinics with access to cryosupernatant, but limited fresh frozen plasma availability, may have another option when stabilizing hemorrhagic dogs. The biggest caveat is the evidence base: just seven retrospective cases, over a long study window, without a control group. (vet.cornell.edu)
What to watch: Whether larger comparative studies test cryosupernatant head-to-head against fresh frozen plasma, including cost, correction of coagulation times, bleeding control, and outcomes. (researchgate.net)
A newly published retrospective case series is putting cryosupernatant on the radar for dogs with suspected vitamin K antagonist rodenticide-associated coagulopathy. Writing in the Journal of Veterinary Emergency and Critical Care, investigators reviewed seven dogs treated between 2000 and 2017 and found that most improved clinically after cryosupernatant transfusion, with significant improvement in prothrombin time and no reported transfusion reactions. (researchgate.net)
The paper addresses a familiar emergency scenario. Anticoagulant rodenticides disrupt hepatic vitamin K recycling, reducing activity of factors II, VII, IX, and X and leading to delayed but potentially life-threatening hemorrhage. In clinical practice, vitamin K₁ remains the backbone of treatment, while plasma or whole-blood products are used to replace active clotting factors in dogs with active bleeding, respiratory compromise, or severe anemia. Cornell’s veterinary diagnostic guidance explicitly lists fresh whole blood, fresh frozen plasma, and cryosupernatant as transfusion options in these cases. (vet.cornell.edu)
In the new series, the dogs had marked coagulation abnormalities at presentation, with median one-stage prothrombin time 697% above control or average of the reference range and activated partial thromboplastin time 393% above reference. After a median cryosupernatant dose of 11.0 mL/kg, prothrombin time fell to a median of 98% of control or average of the reference range, a statistically significant change. Activated partial thromboplastin time also improved in the three dogs with follow-up testing, though the sample was too small for statistical analysis. Six of the seven dogs had resolution of observed hemorrhage and were discharged. (researchgate.net)
The authors are careful not to oversell the findings. This was a retrospective series from a single teaching hospital, spanning 17 years, and all dogs received vitamin K supplementation alongside transfusion support. One dog was euthanized because of multi-organ dysfunction, and the study was not designed to prove that cryosupernatant is superior, or even equivalent, to fresh frozen plasma. Instead, the takeaway is narrower: cryosupernatant appeared clinically useful in this small cohort, even though it contains lower factor IX activity than fresh frozen plasma. (researchgate.net)
That conclusion fits with broader transfusion thinking in veterinary emergency medicine. Prior clinical guidance has described cryo-poor plasma as a reasonable, and sometimes less expensive, option for vitamin K deficiency or antagonism, including anticoagulant rodenticide toxicity. More recently, in vitro work has also explored whether canine cryo-poor plasma can correct vitamin K-dependent coagulopathy, suggesting ongoing interest in whether underused plasma fractions could help expand transfusion options. Because access, storage, and cost remain real constraints in many hospitals, even small studies like this can influence how clinicians think about inventory and emergency preparedness. (dvm360.com)
Why it matters: For veterinarians, the practical value here is optionality. If a hospital already stocks or can prepare cryosupernatant, this study supports the idea that it may help bridge actively bleeding rodenticide patients while vitamin K therapy takes effect. That could be especially relevant in referral and emergency settings where fresh frozen plasma supply is inconsistent, or where cost-sensitive decision-making matters for pet parents. But the evidence is still preliminary, and it shouldn’t displace standard toxicology principles: confirm or strongly suspect an anticoagulant exposure, stabilize the patient, replace clotting factors when bleeding is clinically significant, and continue vitamin K₁ long enough to cover long-acting compounds. (vet.cornell.edu)
There’s also a broader clinical backdrop. Anticoagulant rodenticides remain a common exposure category in dogs and cats, even as the market has shifted over time and non-anticoagulant rodenticides have become more prominent in some consumer products. That means clinicians still need to distinguish anticoagulant intoxication from bromethalin, cholecalciferol, and zinc phosphide exposures, because vitamin K and plasma support are appropriate for one category, but not the others. (vet.cornell.edu)
What to watch: The next meaningful step would be larger, comparative studies that evaluate cryosupernatant against fresh frozen plasma on speed of coagulation correction, hemorrhage control, adverse events, cost, and survival, ideally with more standardized case definitions and follow-up. (researchgate.net)